Ro 64-6198, a selective NOP receptor agonist blocks CGRP-induced migraine-like symptoms and modulates cellular activation
Biochemical Pharmacology · 2026-08 · 250 · 117985
DOI: 10.1016/j.bcp.2026.117985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-08. Verfasst von Ariana Perez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Receptors, Opioid, Calcitonin Gene-Related Peptide, Spiro Compounds. Die Arbeit nennt 50 Literaturangaben. Gefördert von: NIDA NIH HHS, National Institute of Neurological Disorders and Stroke, U.S. Department of Defense.
Abstract (Originalsprache)
The NOP receptor, the fourth member of the opioid receptor family, is found throughout the brain and in the periphery. This receptor is particularly abundant in the trigeminal ganglia and trigeminal nucleus caudalis (TNC), regions intimately involved in cephalic pain, including migraine. Because NOP receptor activation reduces neuronal firing, we have hypothesized that a NOP receptor agonist will block migraine pain and other migraine-associated phenomena such as photophobia. Here we examined the effect of the selective NOP receptor agonist Ro 64-6198 on migraine symptoms induced by systemic administration of both acute and chronic treatment with the migraine-related peptide CGRP. A single injection of CGRP was more effective in inducing periorbital allodynia in male than female mice and this was dose-dependently blocked by Ro 64-6198 (0.3 and 1.0 mg/kg). In female mice chronic treatment (daily for four days) with CGRP induced periorbital sensitivity that lasts at least 24 h after administration and both 0.3 and 1.0 mg/kg Ro 64-6198 blocked both the acute pain and the development of chronic pain. CGRP-induced sensitivity to light (photophobia) was also reversed by 0.3 mg/kg of Ro 64-6198. Ro 64-6198 was not able to block CGRP-induced decrease in locomotion or time spent in the middle of an open field, an indication of anxiety. Finally, Ro 64-6198 also reduced cellular activation in the TNC in CGRP-treated but not vehicle-treated mice suggesting inhibition mostly of CGRP-activated cells. These results suggest that a NOP receptor agonist could be an effective treatment for migraine or other cephalic pain syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA.
- Doctoral School of the Medical University of Lublin, Lublin, Poland; Department of Biopharmacy, Medical University of Lublin, Lublin, Poland.
- Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA; Stiles-Nicholson Brain Institute, Florida Atlantic University, Jupiter, FL 33458, USA.
- Department of Biopharmacy, Medical University of Lublin, Lublin, Poland.
- Department of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA; Stiles-Nicholson Brain Institute, Florida Atlantic University, Jupiter, FL 33458, USA. Electronic address: ltoll@health.fau.edu.
Förderung
- NIDA NIH HHS
- National Institute of Neurological Disorders and Stroke
- U.S. Department of Defense
- Narodowe Centrum Nauki
- US Office of Congressionally Directed Medical Research Programs
Zitieren
APA
Perez, A., Pietrzak-Mitura, D., Mudgal, A., Martinez, M., Lopez, J., Peters, D., Thornberry, J., Mangutov, E., Pradhan, A. A., Cippitelli, A., Ozawa, A., Targowska-Duda, K. M., & Toll, L. (2026). Ro 64-6198, a selective NOP receptor agonist blocks CGRP-induced migraine-like symptoms and modulates cellular activation. Biochemical Pharmacology, 250, 117985. https://doi.org/10.1016/j.bcp.2026.117985
Vancouver
Perez A, Pietrzak-Mitura D, Mudgal A, Martinez M, Lopez J, Peters D, et al. Ro 64-6198, a selective NOP receptor agonist blocks CGRP-induced migraine-like symptoms and modulates cellular activation. Biochemical Pharmacology. 2026;250:117985. doi:10.1016/j.bcp.2026.117985
BibTeX
@article{Perez2026,
author = {Perez, Ariana and Pietrzak-Mitura, Diana and Mudgal, Akanksha and Martinez, Madeline and Lopez, Jefferson and Peters, Darian and Thornberry, Jake and Mangutov, Elizaveta and Pradhan, Amynah A and Cippitelli, Andrea and Ozawa, Akihiko and Targowska-Duda, Katarzyna M and Toll, Lawrence},
title = {Ro 64-6198, a selective NOP receptor agonist blocks CGRP-induced migraine-like symptoms and modulates cellular activation},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {250},
pages = {117985},
doi = {10.1016/j.bcp.2026.117985}
}
EUVIMED